Cost-effectiveness of professional-mode flash glucose monitoring in general practice among adults with type 2 diabetes: Evidence from the GP-OSMOTIC trial.
cost-effective analysis
economic evaluation
flash glucose monitoring
type 2 diabetes
Journal
Diabetic medicine : a journal of the British Diabetic Association
ISSN: 1464-5491
Titre abrégé: Diabet Med
Pays: England
ID NLM: 8500858
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
28
10
2021
received:
03
06
2021
accepted:
16
11
2021
pubmed:
23
11
2021
medline:
23
3
2022
entrez:
22
11
2021
Statut:
ppublish
Résumé
To assess the cost-effectiveness of professional-mode flash glucose monitoring in adults with type 2 diabetes in general practice compared with usual clinical care. An economic evaluation was conducted as a component of the GP-OSMOTIC trial, a pragmatic multicentre 12-month randomised controlled trial enrolling 299 adults with type 2 diabetes in Victoria, Australia. The economic evaluation was conducted from an Australian healthcare sector perspective with a lifetime horizon. Health-related quality of life (EQ-5D) and total healthcare costs were compared between the intervention and the usual care group within the trial period. The 'UKPDS Outcomes Model 2' was used to simulate post-trial lifetime costs, life expectancy and quality-adjusted life years (QALYs). No significant difference in health-related quality of life and costs was found between the two groups within the trial period. Professional-mode flash glucose monitoring yielded greater QALYs (0.03 [95% CI: 0.02, 0.04]) and a higher cost (A$3807 [95% CI: 3604, 4007]) compared with usual clinical care using a lifetime horizon under the trial-based monitoring frequency, considered not cost-effective (incremental cost-effectiveness ratio = A$120,228). The intervention becomes cost-effective if sensor price is reduced to lower than 50%, or monitoring frequency is decreased to once per year while maintaining the same treatment effect on HbA Including professional-mode flash glucose monitoring every 3 months as part of a management plan for people with type 2 diabetes in general practice is not cost-effective, but could be if the sensor price or monitoring frequency can be reduced.
Banques de données
ANZCTR
['ACTRN12616001372471']
Types de publication
Journal Article
Multicenter Study
Pragmatic Clinical Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14747Subventions
Organisme : Department of Health
Pays : United Kingdom
Investigateurs
James Best
(J)
Danny Liew
(D)
Mark Kennedy
(M)
Ralph Audehm
(R)
Sharmala Thuraisingam
(S)
Katie De La Rue
(K)
Louise Ginnivan
(L)
Rebecca Hannam
(R)
Malcolm Clarke
(M)
Amelia Lake
(A)
Andrzej Januszewski
(A)
Informations de copyright
© 2021 Diabetes UK.
Références
Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics. 2015;33(8):811-831. doi:10.1007/s40273-015-0268-9
Lee CMY, Colagiuri R, Magliano DJ, et al. The cost of diabetes in adults in Australia. Diabetes Res Clin Pract. 2013;99(3):385-390. doi:10.1016/j.diabres.2012.12.002
Khunti K, Ceriello A, Cos X, De Block C. Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2018;137:137-148. doi:10.1016/j.diabres.2017.12.004
Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271-281. doi:10.1016/j.diabres.2018.02.023
Wood A, O'Neal D, Furler J, Ekinci EI. Continuous glucose monitoring: a review of the evidence, opportunities for future use and ongoing challenges. Intern Med J. 2018;48(5):499-508.
Speight J, Browne JL, Furler J. Challenging evidence and assumptions: is there a role for self-monitoring of blood glucose in people with type 2 diabetes not using insulin? Curr Med Res Opin. 2013;29(3):161-168.
Manski-Nankervis J, Yates CJ, Blackberry I, et al. Impact of insulin initiation on glycaemic variability and glucose profiles in a primary healthcare type 2 diabetes cohort: analysis of continuous glucose monitoring data from the INITIATION study. Diabet Med. 2016;33(6):803-811. doi:10.1111/dme.12979
Bilir SP, Hellmund R, Wehler E, Li H, Munakata J, Lamotte M. The cost-effectiveness of a flash glucose monitoring system for management of patients with type 2 diabetes receiving intensive insulin treatment in Sweden. Eur Endocrinol. 2018;14(2):80-85. doi:10.17925/EE.2018.14.2.80
Furler J, O'Neal D, Speight J, et al. Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial. Lancet Diabetes Endocrinol. 2020;8(1):17-26. doi:10.1016/S2213-8587(19)30385-7
Furler J, O'Neal DN, Speight J, et al. GP-OSMOTIC trial protocol: an individually randomised controlled trial to determine the effect of retrospective continuous glucose monitoring (r-CGM) on HbA1c in adults with type 2 diabetes in general practice. BMJ Open. 2018;8(7):e021435. doi:10.1136/bmjopen-2017-021435
Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337-343. doi:10.3109/07853890109002087
Viney R, Norman R, King MT, et al. Time trade-off derived EQ-5D weights for Australia. Value Health. 2011;14(6):928-936. doi:10.1016/j.jval.2011.04.009
van Asselt AD, van Mastrigt GA, Dirksen CD, Arntz A, Severens JL, Kessels AG. How to deal with cost differences at baseline. Pharmacoeconomics. 2009;27(6):519-528.
Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56(9):1925-1933. doi:10.1007/s00125-013-2940-y
Harris AH, Hill SR, Chin G, Li JJ, Walkom E. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Med Decis Making. 2008;28(5):713-722. doi:10.1177/0272989X08315247
Huang L, Frijters P, Dalziel K, Clarke P. Life satisfaction, QALYs, and the monetary value of health. Soc Sci Med. 2018;211:131-136. doi:10.1016/j.socscimed.2018.06.009
Edney LC, Haji Ali Afzali H, Cheng TC, Karnon J. Estimating the reference incremental cost-effectiveness ratio for the Australian health system. Pharmacoeconomics. 2018;36(2):239-252. doi:10.1007/s40273-017-0585-2
Edney L, Afzali HHA, Karnon J. Are the benefits of new health services greater than their opportunity costs? Aust Health Rev. 2018;43(5):508-510.
PBAC. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. https://PBAC.pbs.gov.au/ [access 03/Feb/2021]
RACGP. Management of Type 2 Diabetes: A Handbook for General Practice. 2020.
Clarke P, Leal J, Kelman C, Smith M, Colagiuri S. Estimating the cost of complications of diabetes in Australia using administrative health-care data. Value Health. 2008;11(2):199-206. doi:10.1111/j.1524-4733.2007.00228.x
Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22(4):340-349. doi:10.1177/0272989X0202200412
Beaudet A, Clegg J, Thuresson PO, Lloyd A, McEwan P. Review of utility values for economic modeling in type 2 diabetes. Value Health. 2014;17(4):462-470. doi:10.1016/j.jval.2014.03.003
Palmer AJ, Si L, Tew M, et al. Computer modeling of diabetes and its transparency: a report on the eighth mount hood challenge. Value Health. 2018;21(6):724-731. doi:10.1016/j.jval.2018.02.002
Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ. 2013;346:f1049. doi:10.1136/bmj.f1049
Australian Institute of Health and Welfare. Health Expenditure Australia 2018-19. AIHW; 2020.
MedicineWise NPS. MedicineInsight: General Practice Insights Report. 2020.
Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter. Open-label randomized controlled trial. Diabetes Ther. 2017;8(1):55-73. doi:10.1007/s13300-016-0223-6